Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.75 |
| ▸ | MEN1 | O00255 | 3/20 | 0.75 |
| ▸ | PKM | P14618 | 3/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22425029 | 0.83 | KMT2A (0.84) | KMT2AMEN1PKMMAPK1POLB | |
| SCHEMBL26597984 | 0.80 | KMT2A (0.74) | KMT2AMEN1PKMMAPK1POLB | |
| SCHEMBL22425018 | 0.80 | KMT2A (0.69) | KMT2AMEN1PKMMAPK1POLB | |
| SCHEMBL22425031 | 0.77 | POLB (0.84) | KMT2AMEN1PKMMAPK1POLB | |
| SCHEMBL12175766 | 0.77 | PKM (0.63) | PKMPOLBMAPTTP53GAA | |
| SCHEMBL22425020 | 0.77 | TP53 (0.70) | KMT2AMEN1PKMPOLBMAPT | |
| SCHEMBL5972457 | 0.77 | MAPT (0.69) | KMT2AMEN1PKMMAPK1POLB | |
| SCHEMBL18173883 | 0.77 | MAPT (0.79) | KMT2AMEN1PKMMAPK1POLB | |
| SCHEMBL6767870 | 0.76 | TAS2R14 (0.81) | KMT2AMEN1PKMMAPK1POLB | |
| SCHEMBL14403177 | 0.76 | PKM (0.71) | KMT2AMEN1PKMMAPK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708267-B2 | Activators of human pyruvate kinase | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-07-18 | — | — | US | claimed |
| US-20130109672-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICE (US) | 2013-05-02 | — | — | US | claimed |
| EP-2563761-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2013-03-06 | — | — | EP | claimed |
| WO-2011137089-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-11-03 | — | — | WO | claimed |
| US-9708267-B2 | Activators of human pyruvate kinase | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708267-B2 | Activators of human pyruvate kinase | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-07-18 | — | — | US | disclosed |
| US-20150183744-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | US HEALTH (US) | 2015-07-02 | — | — | US | disclosed |
| US-20150183744-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | US HEALTH (US) | 2015-07-02 | — | — | US | disclosed |
| US-20130109672-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICE (US) | 2013-05-02 | — | — | US | disclosed |
| US-20130109672-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICE (US) | 2013-05-02 | — | — | US | disclosed |
| EP-2563761-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2013-03-06 | — | — | EP | disclosed |
| WO-2011137089-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-11-03 | — | — | WO | disclosed |
| WO-2011137089-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183744-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | PDK2, PDK1, PDK3 | KMT2A 469/4885MEN1 2706/4885PKM 6/4885 |
| US-20130109672-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | PDK2, PDK1, PKLR | KMT2A 455/4885MEN1 2510/4885PKM 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.